Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
A UK quality improvement project reports wide variation in emissions and wastage from nitrous oxide sedation, highlighting opportunities to reduce environmental harm while maintaining patient care.
Researchers compare personalized versus standard prehabilitation and examine functional, immune, and postoperative outcomes before major elective surgery.